FREMONT, California, USA, June 2, 2026
Alamar Biosciences has unveiled its NULISA™ Dried Blood Spot (DBS) Extraction Kit, a breakthrough technology designed to make home-collected fingerstick blood samples compatible with ultra-high-sensitivity multiplex proteomics analysis. The launch represents a major advancement in decentralized biomedical research, enabling scientists to generate high-quality proteomic data from remotely collected microsamples without requiring traditional venous blood draws. By extending the capabilities of Alamar’s proprietary NULISA™ precision proteomics platform, the new workflow supports longitudinal, population-scale, and decentralized clinical research programs that were previously difficult to conduct using conventional laboratory collection methods. The innovation addresses a growing demand for scalable, patient-friendly sample collection approaches while maintaining the sensitivity required to detect low-abundance protein biomarkers associated with neurological disorders, inflammatory diseases, and other complex health conditions.
Home-Based Sampling Expands Access to Precision Proteomics
Dried blood spot collection has emerged as an attractive alternative to traditional blood sampling because it enables individuals to provide a few drops of blood from a simple fingerstick procedure that can be shipped at ambient temperature without specialized handling requirements. While this collection method significantly improves accessibility and participant convenience, researchers have historically faced challenges recovering reliable protein signals from extremely small sample volumes.
Alamar’s new NULISA DBS Extraction Kit addresses these limitations through a standardized workflow designed to extract and analyze proteins from both dried blood spot and dried plasma spot microsamples. The technology allows researchers to collect samples remotely from participants located far from major healthcare centers, making large-scale longitudinal studies more practical and cost-effective. By reducing dependence on clinic visits and phlebotomy appointments, the solution may help increase participation rates and improve data collection across diverse patient populations.
Ultra-Sensitive Detection Supports Next-Generation Biomarker Research
Advertisement
The NULISA platform is recognized for its attomolar-level sensitivity, high specificity, flexible multiplexing capabilities, and broad dynamic range, allowing researchers to measure extremely low concentrations of disease-associated proteins. Validation studies conducted by Alamar demonstrated 85% to 95% target detectability across the company’s NULISA CNS and Inflammation panels when used with supported microsampling platforms. This level of performance is particularly important for studies focused on early disease detection and biomarker discovery, where subtle biological signals can be difficult to identify.
Researchers believe the ability to generate reproducible, high-quality proteomic data from fingerstick samples could transform population health initiatives, neurodegenerative disease research, and inflammation studies by enabling more frequent and geographically distributed sample collection. The standardized workflow also improves consistency across different third-party sampling devices, helping ensure reliable results regardless of collection location or platform.
Enabling Decentralized Research at Population Scale
The launch further strengthens Alamar’s position in the rapidly growing precision proteomics sector by connecting remote sample collection directly to the company’s automated ARGO™ HT System and NULISA analytical platform. The workflow supports leading microsampling technologies, including devices from Capitainer, Telimmune, Mitra, and Tasso, creating a flexible ecosystem for decentralized research programs. Industry experts suggest that combining remote sampling with ultra-sensitive protein detection could significantly expand the reach of translational and population-scale studies, particularly in settings where traditional laboratory infrastructure is limited.
As healthcare research increasingly embraces decentralized trial models and digital health technologies, solutions capable of delivering laboratory-grade molecular insights from home-collected samples are expected to play an increasingly important role. With the introduction of the NULISA DBS Extraction Kit, Alamar Biosciences is helping bridge the gap between advanced proteomic analysis and real-world patient participation, enabling a new generation of scalable biomarker-driven research initiatives.
Source: Alamar Biosciences press release
